Slide 1: Nephros, Inc. The Future of Fluid Filtration
NEPHROS, INC. The Future of Fluid Filtration Columbia University - Audubon Technology Center 3960 Broadway New York, NY 10032 PH: 212.781.5113 www.nephros.com
Slide 2: Forward Looking Statements
NEP: Forward Looking Statements This presentation contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such statements may include statements regarding the efficacy and intended use of Nephros' technologies, the timelin
Slide 3: Risk Factors
Risk Factors Factors that may cause such differences include the risks that Nephros may not be able: (i) to obtain funding if and when needed or on favorable terms; (ii) to continue as a going concern; (iii) to liquidate its investments when needed to fund its operations; (iv) to maintain compliance
Slide 4: The Nephros Package: ESRD Therapy and Water Filtration
ESRD (Dialysis) Therapy Water Filtration The Nephros Package Driving ahead with two complementary filtration technologies, with broad market opportunities:
Slide 5: Nephros Delivers A Better Therapy: The OLpur MD Filter
Our advanced proprietary filter designed specifically for advanced-therapy hemodiafiltration (HDF) platforms. Unsurpassed clinical performance in our unique dual-stage design. Priced comparably to current dialyzer products; over 100,000 treatments across Europe so far. Nephros Delivers A Better Ther
Slide 6: Providing HDF Therapy in the US: The OLpur H2H
Convenient add-on module providing upgraded hemodiafiltration capability for standard HD machines , with on-line real-time sterile fluid. Add-on Module Providing HDF Therapy in the US: The OLp ur ™ H 2 H ™ Marketing “razor” for our OLpur MD Filter “razorblades.” Safe, economical means to provide HDF
Slide 7: Nephros Hemodiafiltration (HDF): Bringing a better therapy on-line
Nephros Hemodiafiltration (HDF): Bringing a better therapy on-line… Substantial drug reductions Fewer hospitalizations Reduced infection risk Improved patient nutrition Improved quality of life A 35%+ Reduction in Mortality Risk
Slide 8: Nephros MD HDF: The Value Proposition
Nephros MD HDF: The Value Proposition Appropriate for all patients U.S. patient population includes incident (new) patients; those with vascular access issues; pediatric patients. Prime target markets. Nephros is driving to be the predominant provider of HDF therapy in the US by 2009. ESRD patients
Slide 9: Where are we today with Nephros Hemodiafiltration?
Where are we today with Nephros Hemodiafiltration? U.S. clinical trial completed : 24 patients, 3 months using Nephros Mid-Dilution Therapy. Over 34,000 liters of fluid injected into patients, purified in real- time by the Nephros H 2 H module, with no adverse reactions Now preparing FDA 510(k) subm
Slide 10: Water Filtration Technology
Our ESRD therapy research has produced a cost-effective, robust The Nephros Dual Stage Ultrafilter (DSU) effectively addresses a range of biologically contaminated water problems… Water Filtration Technology
Slide 11: Water Filtration Business Drivers
Water Filtration Business Drivers 2 Million Hospital Acquired Infections per year in the U.S. alone, with 100,000 deaths and $30 BILLION in additional healthcare costs (over $12,000 on average per case). Water has been identified as a primary source of infection . Recent study: 14 of 20 major U.S. h
Slide 12: What does the Nephros DSU bring to the table?
What does the Nephros DSU bring to the table? Removes bacteria, fungi, viruses, parasites, and biological toxins (including ricin, cryptosporidium, and botulinum toxin), dramatically exceeding purification requirements for potable water Effective end-point filtration reduces or eliminates the need f
Slide 13: Nephros DSU substantially outperforms the competition in endurance
Nephros DSU substantially outperforms the competition in endurance Competition’s flow dropped under the 1 gallon/minute minimum in 30 minutes of use Nephros DSU flow sustained above 1.2 gallons/minute after more than 4 weeks at 30 minutes/day
Slide 14: Nephros DSU outperforms competition in removing bacteria, viruses and toxins
Water Salts & Minerals Clostridium Botulinum toxin Ricin toxin Staphylococcal enterotoxin B Ebola virus Smallpox; Polio Hepatitis A, E Giardia Lamblia Cryptosporidium Klebsiella pneumoniae Bacillus anthracis E. Coli & Salmonella Vibrio cholerae Legionella pneumoniae Mycobacterium Pseudomonas aerugin
Slide 15: The Nephros DSU: Proven Stopping Power
The Nephros DSU: Proven Stopping Power
Slide 16: Nephros DSU: A New Water Filtration Standard
Nephros DSU: A New Water Filtration Standard Reliability <<>> Purity <<>> Simplicity <<>> Adaptability The difference between unfiltered water and Nephros Filtration in black and white
Slide 17: Where are we today with the Nephros DSU?
Where are we today with the Nephros DSU? Tests at two major northeast hospitals demonstrated product efficacy and durability NSF testing to standard P231, microbiologically pure water, to be completed this summer Filter is currently in test at a major New York hospital Currently commercializing and
Slide 18: The Nephros Opportunity
The Nephros Opportunity Complementary technologies with broad market opportunities in ESRD therapy and water filtration Business plan with defined goals Management experience; a revitalized board and team U.S. clinical trials now completed Active distribution business with CE marked products in Euro
Slide 19: Financial Overview
Financial Overview
Slide 20: Statement of Operations
Statement of Operations Q1 2008 Net Revenues $387 Gross Profit $149 GP % 38.5% Op Exp $1,925 Loss Ops ($1,776) Other $136 Net Loss ($1,640) Q1 2007 Net Revenue $296 Gross Profit $ 91 GP % 30.7% Op Exp $1,609 Loss Ops ($1,518) Other ($ 53) Net Loss ($1,571)
Slide 21: Balance Sheet
Balance Sheet March 31, 2008 Current Assets $3,724 L/T Assets $5,037 Current Liabs $1,532 L/T Liabs $ 0 Equity $7,229 December 31, 2007 Current Assets $9,296 L/T Assets $ 789 Current Liabs $1,329 L/T Liabs $ 0 Equity $8,756
Slide 22: Nephros, Inc.
NEPHROS, INC. The Future of Fluid Filtration Columbia University - Audubon Technology Center 3960 Broadway New York, NY 10032 PH: 212.781.5113 www.nephros.com